Pargyline

Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities[1][2][3]. Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[555-57-7]

UNSPSC

12352005

Hazard Statement

H227, H301+H311+H331, H315, H319, H335

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Pargyline.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C#CCN(C)CC1=CC=CC=C1

Molecular Formula

C11H13N

Molecular Weight

159.23

Precautions

H227, H301+H311+H331, H315, H319, H335

References & Citations

[1]C J Fowler, et al. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31 (22) :3555-61.|[2]Hyung Tae Lee, et al. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30 (4) :1587-92.|[3]Fuentes JA, et al. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57 (1) :21-7.